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Total-body contrast-enhanced MRA on a short,
wide-bore 1.5-T system: intra-individual
comparison of Gd-BOPTA and Gd-DOTA
Abstract Total-body contrast-
enhanced MRA (CE-MRA) provides
information of the entire vascular
system according to a one-stop-shop
approach. Short, wide-bore scanners
have not yet been used for total-body
CE-MRA, probably due to their re-
stricted field of view in the z-direction.
The purpose of this feasibility study is
to introduce an image protocol for
total-body MRA on a short, wide-bore
system. The protocol includes five to
six table-moving steps and two injec-
tion runs. Two pharmacologically
different contrast materials (CM) were
applied in ten healthy volunteers in
view of possible CM-dependent in-
fluences on the protocol outcome
(Gd-Bopta, Gd-Dota). Differences
consisted of significantly higher CNR
with Gd-Bopta with a mean of 73.8±
38.7 versus 69.1±34.3 (p=0.008),
significantly better arterial visualiza-
tion values with Gd-Dota with a mean
of 1.26±0.44 versus 1.53±0.73 (p=
0.003) and a tendency to less venous
overlay with Gd-Dota, mean 1.19±
0.44 and 1.34±0.72, respectively (p=
0.065) (two-tailed Wilcoxon matched-
pairs test). Overall 94% of the steps
were valued as qualitatively excellent
or good. The good results with both
CM suggest a transfer to further
patient evaluation.
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Introduction
Contrast-enhanced MR angiography (CE-MRA) has
emerged as a robust, safe and reproducible alternative to
digital subtraction angiography for the evaluation of
peripheral arterial occlusive disease (PAOD) [1–10].
Total-body 3D contrast-enhanced magnetic-resonance
angiography is well suited for the assessment of the
peripheral vasculature. In addition, it provides additional
data regarding the remaining arterial vessel system [11,
12] according to a one-stop-shop approach. Patients
with peripheral arterial disease are frequently found to
have additional atherosclerotic lesions in the coronary,
renal, and carotid arteries [13]. An impact on patient
management in patients with PAOD has been reported
[11].
Recently published whole-body CE-MRA data revealed
in approximately half of the patients with coronary heart
disease at least one additional relevant stenosis in the arterial
vasculature including the peripheral, renal and internal
carotid artery. This finding underlines the clinical potential
of CE-MRA for a certain collectives of patients [8].
Pre-results of the material have been
presented at the RSNA, Chicago (2006),
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Short, wide-bore scanners are intended to provide
increased patient comfort due to the shorter length of the
scanner and wider gantry diameter (length 125 cm, diam-
eter 70 cm) in comparison to 1.5-T long-bore scanners. The
drawback of the short magnet design is accompanied by a
field-of-view reduction in z-direction. For total-body
MRA, this reduction in spatial extension demands an
additional acquisition step to cover the total body. This
yields to an extension of acquisition time. Its influence on
image quality concerning arterial enhancement, venous
overlay and rim artifacts is presently unclear.
The purpose of this feasibility study is to implement a
multi-step imaging protocol for total-body MRA on a
short, wide-bore system. The imaging protocol consists
of five to six automated table steps and two separate
intravenous injections. Two contrast media with differ-
ent pharmacokinetic properties, one with weak albumin
binding [14, 15] and one unspecific extracellular
substance [16], are applied to evaluate possible phar-
macokinetic influences on the protocol outcome. In
comparison the weak albumin-binding contrast material
is known to tend towards higher and longer vascular
peak enhancement [14, 17]
Materials and methods
The study was approved by the local ethics committee; all
volunteers gave written informed consent. Ten healthy
volunteers (mean age 27.9, 21–41 years; male:female 6:4;
mean height 172.7, 160–185 cm; mean weight 70.0 kg, 50–
88 kg) were enrolled. All volunteers underwent two total-
body CE-MRAs, each with Gd-Bopta (Gadobenate
dimeglumine, Multihance®, Bracco Suisse S.A., Mendrisio,
Switzerland [14, 15]) and Gd-Dota (Gadoterate meglumine,
Dotarem®, Guerbet, Aulnay-sous-Bois, France [16]) in
random order with at least 7 days in between. Both contrast
materials (CM) correspond to 0.5 mmol/mL gadolinium
solution.
MR imaging
All measurements were performed on a Magnetom Espree
scanner (1.5 T, Siemens, Erlangen, Germany; bore diam-
eter 70 cm, length 125 cm,) equipped with whole-body
array surface coils. A 3D-FLASH (fast low angle shot)
sequence with field of view (FOV) 385 mm/step, step
width 300 mm, resulting in an overlap of 42.5 mm between
all neighboring steps. Acquisition parameters of the two
injection protocol are presented in Table 1.
Parallel imaging with GRAPPA algorithm (generalized
autocalibrating partially parallel acquisition) was used
(GRAPPA-factor 2 for steps a, e, f and GRAPPA-factor 3
for b, c, d). Higher GRAPPA accelerations, especially in
the peripheral steps, were a priory abandoned to prevent
expectable consecutively increased signal intensity loss.
The acquisition steps covering supraaortic and calf
arteries (steps a,e) are acquired with the first contrast
injection run, thoracic, abdominopelvic, upper leg and
feet arteries (steps b, c, d, f) with the second injection
(Fig. 1).
The protocol provides double dynamic properties, which
means that the last steps of each injection run (e,f) might be
repeated if dynamic vascular information of the calf and
foot arteries are desired. In this setting with healthy
volunteers, the last step of the first injection run was
exemplarily repeated three times (Fig. 1, Table 1, Fig. 5); a
repetition of step f was rejected, because no pathologies or
delayed vascular enhancement was expected. Both injec-
tions were adapted to body weight (BW), (0.3 ml CM ×
BW)-2 ml and followed by saline flush (30 ml at 2 ml/s;
Spectris® MR Injection System, Medrad, Inc, Indianola,
Pa; flow rates of each injection; Table 1). The test bolus
[18] used for the first run consisted of 2 ml CM
followed by saline flush. The care bolus [18] of the
second run was followed by subtraction mask acquisi-
tion for the second injection steps. Between the first and
second injection were a mean of 6.5 min (±2.73)
duration. Net acquisition time, including localizer, bolus,
Table 1 Sequence parameters (3D-FLASH) in chronological order: steps a and e are measured with the first injection’s CM, timed by test
bolus; the second injection is started depending on the care bolus for the acquisition of steps b, c, d and f
Injection Step FOV read [mm] FOV phase [%] Voxel size [mm3] TR [ms] TE [ms] BW [Hz/Px] TA [s]
Test bolus 2 ml at carotid level, native acquisition for subtraction: e, a
1st at 2 ml/s a 300 67 1.1×0.8×1.1 4.31 1.39 410 19
e 385 92 1.0×1.0×1.0 3.54 1.37 510 3×25
Care bolus 2 ml at thoracic level, native acquisition for subtraction: c, d, f, b
2nd at 50% 2 ml/s 50% 0.7 ml/s b 385 100 1.5×1.0×1.5 3.13 1.15 520 13
c 385 100 1.6×1.0×1.5 3.12 1.14 520 10
d 385 100 1.5×1.0×1.5 3.13 1.15 520 10
f 385 92 1.0×1.0×1.0 3.54 1.37 540 25
Subtraction masks/native datasets for post-acquisition-calculation of subtracted images are taken with equal parameters before step a (a, e),
respectively, in between angiographic acquisitions/before step b (b, c, d, f). TA = acquisition time
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native and dynamic contrast-enhanced (CE) acquisition
times amounted to 11:18 min. Approximated whole
examination “in-room” duration was about 40 min.
Qualitative and quantitative evaluation, statistics
The protocols outcome was valuated on the basis of
qualitative image analysis. In addition, quantitative
analyses were performed to indicate and quantify possible
CM-dependent influences. An additional assessment of all
data, including all MIP and source image data, was
performed in view of exclusion of vascular pathologies.
Qualitative analysis consisted of a blinded consent
reading of two experienced radiologists (>10 years of
experience) who valued subtracted maximum intensity
projection (MIP) images of each step toward venous
overlay (VO) and arterial visualization (AV). Both
parameters range from I to IV, with
(I) (VO) Excellent, no venous overlay; (AV) excellent
arterial visualization
(II) (VO, AV) Fair, observer confident
(III)(VO, AV) Poor, observer not confident
(IV)(VO) Non-diagnostic due to venous overlay; (AV)
insufficient arterial contrast.
Quantitative analysis consisted of contrast-to-noise ratio
(CNR) measurements of 30 arterial segments (unpaired
arterial segments: basilary artery, thoracic aorta, supra-
renal abdominal aorta, infrarenal abdominal aorta; paired
segments: internal carotid, common carotid, subclavian,
renal, common iliac, common femoral, proximal half of
superficial femoral, distal half of superficial femoral,
popliteal, tibioperoneal trunk, anterior tibial, peroneal,
posterior tibial arteries).
CNR was defined as: CNR=(SI − SItissue)/Noise with
SI = mean intra-arterial-ROI signal intensity measured
from the source image with best visualization of each
arterial segment; SItissue = mean signal of equal ROI size
within adjacent tissue of each segment measured on the
same slice as the arterial segment; noise = standard
deviation of surrounding air’s signal measured on one of
the source images of each step within the FOVand outside
the body within an area of equalized size and position
between both CM datasets >50 pixel.
To compare data from the subtracted MIP images and
data from the source images, an additional parameter
“contrast sum” (CS, CS_mip, respectively) was introduced.
Contrast sum was defined as CS = (SI − SItissue) and
accordingly for data evaluated from the subtracted MIP
images CS_mip = (SI_mip − SItissue_mip).
For statistical analysis the two-tailed Wilcoxon matched-
pairs test was used in accordance to the intra-individual
comparison setting (SPSS 14.0; indication of significance
p<0.05).
Fig. 1 Injection scheme with first and second injection run,
covering in head-foot direction steps a and e, respectively, b to d
and f. The lower steps e and f can be repeated in view of additional
dynamic information (= dynamic property) if dynamic vascular
information is desired. In this series of healthy volunteers, limited
exemplary dynamic measurements of step e (Table 1, Fig. 5) were
applied
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Results
No vascular pathology was found. No major adverse event
occurred [19]. One volunteer suffered temporarily from
low blood pressure after Gd-Bopta injection with sponta-
neous recovery without further medication. The number of
table-moving steps was six in eight of ten volunteers; in
two the protocol had to be reduced to five steps, as the body
length was <170 cm, resulting in n=116 steps, 58 steps with
each CM, respectively.
Quantitative analysis
WithGd-Bopta significantly highermean arterial SI (490versus
435, p<0.001) andSI_tissue (105versus 88, p<0.001) resulted,
accompanied by higher CNR values. The significant difference
of mean CNR amounted to 73.8±38.7 versus 69.1±34.3 (p=
0.008) in comparison. CS showed an also significant difference
(385 versus 346, p<0.001). CS_mip revealed higher values in
comparison to CS for both CM. Between the mean CS_mip
values of each CM no significant difference was found (508
versus 518, p=0.12). The difference between mean CS and
mean CS_mip (= mean CS - mean CS_mip) amounted to 133
(385–518) within the Gd-Bopta results and 162 (346–508)
within the Gd-Dota results. Numeric results are given in
Table 2, subdivided for each contrast material for the quanti-
tative parameters’ signal intensity (SI), signal intensity of tissue
(SI_tissue), contrast-to-noise ratio (CNR), contrast sum (CS)
and contrast sum of subtracted MIP images (CS_mip).
Lower contrast-to-noise ratio values were observed in
steps b and c for both CM, in comparison to steps a, d, e.
Box plots of the stepwise subdivided CNR values are
presented in Fig. 2.
Qualitative analysis
Arterial visualization was subdivided into acceptable (I,
II) and compromising steps (III, IV); 7 of 116 (6%) steps
were valued as of poor or non-diagnostic arterial
visualization (III, IV). Compromising AV occurred
exclusively in steps of the second run, distributed from
thoracic to foot level (Table 3).
The distribution of steps with AV of III or IV revealed
one compromising step with Gd-Dota and six with Gd-
Bopta with a significant mean difference of 1.26±0.44
versus 1.53±0.73 (p=0.003).
For venous overlay overall also 7 of 116 (6%)
compromising steps resulted. Compromising VO occurred
mainly in steps a and e of the first injection run (Table 3).
Steps with compromising VO included one compromising
step measured with Gd-Dota and six with Gd-Bopta with
mean 1.19±0.44 versus 1.34±0.72 (p=0.065) (Table 3).
Discussion
Total-body CE-MRA on a short, wide-bore scanner with a
two-injection protocol is feasible. Qualitatively valuable
images were acquired for two pharmacologically different
contrast materials in an intra-individual comparison in ten
healthy volunteers.
In contrast to previous studies performed on long-bore
scanners [5, 11, 18, 20, 21], one additional step is needed to
compensate the short extension in z-direction.
The acquisition time (Table 1) was between 10 to
25 s/step, net acquisition time 11.18 min, plus duration in
between both injections. Complete in-room duration was
about 40 min. Acquisition time and approximated achiev-
able in-room durations in a post-experimental setting are
comparable to other acquisition schemes [8, 11, 20, 21]
with TA per step between of 12 s [11], 13–17 s [20], 19 s
[8] or 13–23 s [21], and a reported net acquisition time with
two injections of 19:53 min [21] or 40 min for a one
injection protocol, but including further examination parts
(head, heart) [8] were reported.
A multi-station protocol with two separate contrast
media injections [9, 10] was used, as proposed for total-
body MRA for conventional scanners [20, 21]. In general,
Table 2 Comparative analysis of quantitative parameters, taken from the whole group of all volunteers and vessel segments (10×30) for
each contrast material (two-tailed Wilcoxon matched-pairs test, indication of significance p<0.05)
SI SI_tissue CNR CS CS_mip
Dota Bopta Dota Bopta Dota Bopta Dota Bopta Dota Bopta
Mean 434.6 489.8 88.4 104.8 69.1 73.8 346.3 385.0 507.8 517.5
Median 371.0 417.0 79.0 95.5 65.4 66.3 280.5 313.5 457.0 464.5
SD 206.4 228.6 40.1 51.8 34.3 38.7 191.0 216.0 265.4 292.9
Min 168.0 174.0 31.0 27.0 13.2 8.5 87.0 75.0 101.0 83.0
Max 1,096.0 1,281.0 262.0 395.0 180.5 217.5 954.0 1,080.0 1,957.0 1,952.0
25% 278.5 315.3 57.0 65.3 42.9 45.8 208.0 228.0 332.3 318.0
75% 556.8 628.3 115.8 136.8 91.8 99.3 461.8 511.8 632.8 633.8
p<0.001 p<0.001 p=0.008 p<0.001 p=0.120
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there are at least two advantages of a two injection regime.
First, reduction of venous overlay was reported [20].
Secondly, an increase of contrast within supraortal and
body segments was found [21]. Both findings might be
explained by optimized bolus chasing during the arterial
CM passage.
Due to the field inhomogeneity of the static magnetic
field, signal loss artifacts at the steps rims occurred. Those
Fig. 2 Box plots of CNR values for Gd-Dota (dota) and Gd-Bopta (bopta), subdivided in steps a to e. At zero level mean values and SDs
are shown; numbers of included vessel segments/step/CM are a: 70, b: 50, c: 54, d: 44, e: 82
Table 3 Comparative analysis of qualitative parameter arterial visualization (AV) and venous overlay (VO), taken from the whole group of
n=58 steps for each contrast material (two-tailed Wilcoxon matched-pairs test, indication of significance p<0.05)
AV VO
Dota Bopta Dota Bopta
I or II 57 52 57 52
III – 6 (b,b,c,c,d,f) 1 (a) 5 (a,a,e,e,f)
IV 1 (f) – – 1 (d)
Mean 1.26 1.53 1.19 1.34
p=0.003 p=0.065
The distribution of given values are grouped into acceptable steps (I and II) and compromising steps with values of III and IV, for which
detailed step origin is given in brackets
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could be widely reduced by generous overlapping of the
adjacent images of 4.25 cm within the composed whole
body projections (Figs. 3, 4). Even though duration was in
between both injections, a slight venous overlay originat-
ing from the first injection was expected for the later steps.
Thus, subtraction mask acquisitions for the second
injection’s steps were positioned in between both injec-
tions (Fig. 1, Table 1) to achieve a wide reduction of this
possible effect.
Both CM provided good and sufficient arterial visual-
ization. Only few steps were compromised due to
insufficient arterial visualization or disturbing venous
overlay. Within this limited collective, qualitative results
of the protocol with both CM are comparable.
An apparent difference between qualitative and quanti-
tative results was found: Significantly higher SI and CNR
values resulted for Gd-Bopta (mean CNR difference 74
versus 69, p=0.008, Fig. 2), which was also observed in
other studies [14, 17, 22]. However, Gd-Dota revealed at
least equal image quality with even significantly better
arterial visualization-even though with lower SI and CNR
values. The reason might be partially explained by the
underlying quantification parameter that corresponds
closest to the basis of qualitative valuation of arterial
visualization: CS_mip, measured from the subtracted MIP
reconstructions. Whereas all quantitative parameters mea-
sured from the source image data (SI, CNR, CS) resulted in
a significant difference, the only quantitative parameter
based on the subtracted MIP images did not reveal a
significant difference between both CMs. We assume that
due to the subtraction process and the voxel selection of
MIP reconstruction, the quantitative results of both CMs
approximated (that circumstance is also indicated by the
comparison between CS and CS_mip of each CM, which
revealed a relatively higher difference between CS and
CS_mip for Gd-Dota than for Gd-Bopta). Before the
background of an insignificant quantitative difference of
Fig. 3 Example of Gd-Dota (dota) and Gd-Bopta (bopta),
composed total-body MRA of one volunteer
Fig. 4 Intra-individual comparison of lower legs, step e. Upper row:
Arterial visualization (AV) and venous overlay (VO) of both
contrast materials were valued as I = excellent. Lower row: Step e of
another volunteer with AV = 1 for Gd-Dota, II for Gd-Bopta and
VO = II, respectively, III for Gd-Bopta. Artifacts with loss of arterial
contrast can be seen at the upper and lower rim in Z direction.
Within the total body compositions those effects are widely
eliminated by overlapping of 4.25 cm at each rim
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the subtracted MIP data, the qualitative AV result seems
more congruent. Besides within the qualitative valuation
data (range I–IV), the majority of corresponding steps
showed equal results (“ties”). Exceptions were mainly
presented by the higher number of compromising steps in
one group, which mainly led to the significance of
difference. Thus, the results indicate, that post-processing
procedures do have an influence on the arterial visualiza-
tion outcome and may somehow soften the effect of
underlying quantitative parameter’s superiority of source
image data (SI, CNR, CS). However, with both CMs the
overwhelming number of steps provided acceptable AV
results.
The qualitative parameter venous overlay revealed a
difference between both CMs with a tendency to more
venous overlay with Gd-Bopta within this setting (Table 3).
Gd-Bopta is known to have different pharmacokinetics
with mild albumin-binding properties with a higher
relaxivity and longer vascular peak enhancement. It can
be expected-and was also demonstrated in our study-that
stronger vascular enhancement leads to higher vessel
contrast both in the arterial and venous phase. The
influence on image evaluation concerning venous overlay,
however, was reported to seem to be of minor importance,
as recently demonstrated in peripheral artery disease
patients [22]. According to the different measurement
protocol used, comparability is limited. In our setting the
prolonged vascular enhancement seems to have led to a
venous overlay increase in some of the steps, hampering
the arterial evaluation. However, the relatively low number
of steps with disturbing venous overlay in general in this
setting does not allow sufficient statistical proof of
causality.
It has to be admitted that in this study with healthy
volunteers the focus was on image quality and not
valuation of pathologies. In accordance it was desirable
to differentiate even slight differences of AV and VO and
not to distinguish between diagnostic or nondiagnostic
imaging, as pathologies were not even expected.
Thus, the source image data were not included in the
qualitative valuation, because the MIP reconstructions
concentrate all data concerning VO and AV to one image
and thus allow a better differentiating between slight effects
than the whole set of source image data can provide.
Both CMs tended towards notably higher CNR values
within the peripheral steps compared to central segments
Fig. 5 Source images of step e of both CMs of one volunteer
showing the dynamic properties of the protocol. The three
repetitions are shown from left to right as e1 = 1st measurement,
e2 and e3 = repetitions. A little loss of arterial signal intensity can be
seen, as well as a slight increase of venous signal intensity (cut-
outs). MIP reconstructions of this volunteer were valued with 1 for
AV and VO for both CMs
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such as the thoracic and abdominal aorta (Fig. 2). The
effect has already been described [22]. The reason for this
finding is not completely understood and is likely to be
influenced by many factors, such as distribution of CM,
surrounding tissues like the lung and intestine and
increased coil sensitivity due to less distance to the
target region. Besides an increase of GRAPPA acceler-
ation is known to lower SI and depending CNR, which
might have influenced this finding, as well as the
GRAPPA factor was 3 in the thoracoabdominal steps
versus 2 in the peripheral and supraaortic steps. In
contrast, the lower resolution in those steps will have
diminished the effect, as a lower resolution generally
results in higher SI and vice versa.
A major limitation of the study is that the collective of
young, healthy and compliant volunteers is highly selec-
tive. Potential compromising effects such as lower contrast
within the body segments and loss of exactness due to
motion and deviation of bolus time, etc., might become
somehow more critical in patients and may lead to a
reduction of quality. Further evaluation in PAOD patients is
necessary to prove the clinical value of total-body CE-
MRA using a short, wide bore-system in comparison to
established 1.5-T protocol results. Potential modifications
for optimized patient evaluations may be on the one hand
adaptions of the presented protocol itself, e.g., further
reduction of step length to reduce rim artifacts and an
increase of overlay or reduction of resolution within the
central steps to reduce aquisition time. On the other hand,
additional techniques such as calf compression [7, 11, 13,
23–26] or continuous acquisition techniques [27, 28] may
provide further improvement for short, wide-bore scanner
angiography. It seems likely that with only minor
adaptations the protocol will be feasible for clinical
practice as an additional option besides established long-
bore scanner MRA protocols.
In conclusion, the overall good results with both CM of
total-body contrast-enhanced MRA using a short, wide-
bore scanner suggest a transfer to further patient evalua-
tion. Gd-Bopta provided better source image SI, whereas
the subtracted MIP data sets showed better mean arterial
visualization and a tendency to less venous overlay with
Gd-Dota within this setting (Fig. 5).
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